Objective: United States Food and Drug Administration (FDA)-mandated postapproval studies have long been a mainstay of the continued evaluation of high-risk medical devices after initial marketing approval; however, these studies often present challenges related to patient/physician recruitment and retention. Retrospective single-center studies also do not fully represent the spectrum of real-world performance nor are they likely to have a sufficiently large enough sample size to detect important signals. In recent years, The FDA Center for Devices and Radiological Health has been promoting the development and use of patient registries to advance infrastructure and methodologies for medical device investigation. The FDA 2012 document, "Strengthening the National System for Medical Device Post-market Surveillance," highlighted registries as a core foundational infrastructure when linked to other complementary data sources, including embedded unique device identification. The Vascular Quality Initiative (VQI) thoracic endovascular aortic repair for type B aortic dissection project is an innovative method of using quality improvement registries to meet the needs of device evaluation after market approval. Here we report the organization and background of this project and highlight the innovation facilitated by collaboration of physicians, the FDA, and device manufacturers.
The United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) is responsible for the regulation of most medical devices in the United States, with a small proportion of medical devices being regulated by the Center for Biologics Evaluation and Research (CBER). Approval of new, high-risk devices is typically supported by clinical data demonstrating a reasonable assurance of safety and effectiveness in a select group of patients treated at specialized centers. Data from clinical trials leading to The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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Copyright market approval are communicated to physicians in the instructions for use for devices. Because the real-world use of such devices is often broader than the clinical study used to determine safety and effectiveness, a postapproval study (PAS) may help to provide additional information regarding device performance in routine clinical practice. Such studies allow for the evaluation of subgroup performance (eg, acute, chronic dissection), learning curve assessment, assessment of the effectiveness of training programs, or refinement of the risk/ benefit balance in the real-world setting.
In the absence of a national postmarket surveillance infrastructure, the FDA historically relied on standalone PASs sponsored by industry for mandated postmarket device evaluation. Unfortunately, enrollment in such studies can be difficult, because patients can be treated outside of the clinical trial setting. Further, these studies can be burdensome to conduct due to significant expense and the need for long-term follow-up.
The FDA has been driven by a desire to strengthen medical device evaluation and to build a United States national infrastructure that would enable appropriate premarket and postmarket data collection and is working on major changes to the device evaluation infrastructure. These changes include use of existing clinical registries 1 linked to complementary data sources, augmented by the Unique Device Identifier system. [2] [3] [4] [5] [6] The purpose of this report is to outline the context, methods, and current status of the Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) Thoracic EndoVascular Aortic Repair (TEVAR) of type B aortic dissection project. Here we describe this innovative project using existing national VQI data collected for quality improvement purposes to monitor real-world device performance after market approval. As a unique early demonstration project, this effort has informed the national FDA CDRH strategy for medical device evaluation.
THE SVS VQI
With the growing interest in quality in medical care, the SVS created a Patient Safety Organization (PSO) and implemented the VQI in 2011 to capture procedural and device-specific data and outcomes for common vascular procedures. The independent PSO, designated by the Agency for Healthcare Research and Quality (AHRQ), facilitates the collection and analysis of these data for quality improvement purposes, while safeguarding confidentiality. The mission of the VQI is to improve the quality, safety, effectiveness, and cost of vascular health care by collecting, analyzing, and exchanging information. 7 Data are captured in individual procedural registries and include device-specific data that can be used to monitor the performance of devices in realworld use. Participation in any VQI registry requires an agreement to enter all consecutive eligible cases, which is audited by comparison with claims data to avoid selection bias based on outcome. The VQI has been rapidly adopted and currently includes 376 nationwide centers with >2900 participating physicians of different specialties, including cardiologists, radiologists, and cardiothoracic and vascular surgeons, and >275,000 patients. In addition, the VQI comprises an even mixture of academic, teaching-affiliated, and community hospitals, which provide a geographically balanced representation of realworld vascular practice in the United States (Fig 1) .
The VQI Thoracic & Complex EVAR Registry captures detailed information regarding patient demographic and historical data, procedural data, and outcomes up to 1 year after the procedure for patients treated for the most common thoracic and thoracoabdominal aortic pathologies (eg, dissection, aneurysm, traumatic injury). To date, this registry has collected data for >6500 procedures.
TEVAR FOR AORTIC DISSECTION
Complicated Stanford type B (DeBakey IIIa/b) aortic dissection has seen an enormous shift in management from open surgical to endovascular treatment in recent years and is now a common indication for TEVAR. 8 The use of TEVAR devices for this indication has increased dramatically since initial FDA approval of devices specific for the treatment of type B dissection in 2013. The Gore TAG (W. L. Gore & Associates, Flagstaff, Ariz) and Medtronic Valiant (Medtronic, Inc, Santa Rosa, Calif) devices were given broad dissection approval by the FDA for the treatment of descending thoracic aortic pathology based on premarket trials focused on acute dissection complicated by end-organ malperfusion or rupture. These FDA approvals came with the requirement to further evaluate the use of these devices for treatment of all presentations of type B dissection (ie, acute, chronic, uncomplicated, complicated) to include those indications that were not part of the premarket dissection trials. Given the complexity and variability in patient anatomy and presentation with type B dissection, the application of TEVAR devices in routine clinical practice does not represent the strict anatomic guidelines and clinical presentations outlined in industry-sponsored trials. In addition, the premarket studies were not designed to answer the multitude of questions associated with TEVAR treatment of dissections, such as when to treat and how much of the aorta to cover. For all of these reasons, the FDA required further evaluation of these devices. The collaborative group that arranged this project envisioned that it would fulfill the CDRH commitment to appropriately balance premarket and postmarket data collection during FDA review of premarket approval applications.
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COLLABORATIVE TEVAR SURVEILLANCE PROJECT
In an unprecedented collaborative effort to define a new approach to device evaluation in real-world use, a multistakeholder group collaborated to develop a protocol for postapproval surveillance of TEVAR devices in realworld treatment of Stanford type B dissection. The group included representatives from professional medical societies (SVS, The Society of Thoracic Surgeons, American Association of Thoracic Surgeons, and Society of Interventional Radiology), industry, and the FDA. The project protocol included definitions of events, treatment success, end points, sample size calculations, data fields, and analysis methods.
The project required significant groundwork in preparation to begin data collection and eventual analysis, including revision of the SVS VQI Thoracic & Complex EVAR Registry to accommodate additional data points required for adequate surveillance after TEVAR for dissection. These efforts included overall enhancements to the registry that have facilitated data collection for quality improvement purposes as well. Importantly, data elements that were added to answer questions of interest did not modify standard of care, just achieved the documentation of standard of care.
Patient cohorts. The project consists of (1) a cohort of patients monitored through 5 years postprocedure at centers that agreed to report follow-up beyond the standard 1-year follow-up reporting in VQI, and (2) a cohort of patients monitored for 1-year postprocedure per standard VQI reporting practice. Because collection of data for quality improvement within a PSO does not require informed consent or Institutional Review Board approval, this was not required for this project. Only nonidentifiable data were used for analysis, and Institutional Review Boards do not consider publication of nonidentifiable data as human subjects research.
Data collection. The data forms for this project consist of the VQI Thoracic & Complex EVAR Registry, with additional fields to capture additional data and longer followup for the 5-year cohort. Additional data for this cohort include preoperative and postoperative imaging details regarding anatomic characteristics of the dissection and the relative location of the TEVAR device. Preoperative and postoperative imaging data are reported based on computed tomography arteriogram or magnetic resonance arteriogram. Imaging data for patients in the 5-year cohort will be collected at least at yearly intervals after the initial 30-day follow-up. The 5-year cohort was specified to include at least 200 acute and 200 chronic dissection patients, with at least 60 patients treated using each of the manufacturers' devices for each dissection type.
The 1-year cohort will include 200 patients and requires the usual data collected in the Thoracic & Complex EVAR Registry. This cohort was designed to encourage participation by centers that otherwise might not have the infrastructure to collect additional data and ensures broad enrollment by centers representing all varieties of medical practice.
Project governance and support. Funding was provided to the SVS PSO by industry and has been used for the registry development needed to accommodate additional data, data monitoring and reporting, and for reimbursement by the SVS PSO to centers that agreed to submit additional data and follow-up for relevant patients treated during this device quality assessment project. The multidisciplinary team involved in project design included FDA premarket and postmarket clinical, statistical, epidemiologic, and engineering expertise.
The project Steering Committee includes members of the VQI experienced with TEVAR for the treatment of dissection. This group has overseen project budgeting, site selection, data collection, and data evaluation. The efficiency of the project setup and execution has been facilitated by the expertise provided by members of the group and an ongoing collaboration with industry and the FDA.
Site selection. At the project inception, an invitation was extended by the SVS PSO to centers that already enter data in the Thoracic & Complex EVAR Registry. The Steering Committee then evaluated interested institutions by their overall historical registry performance (enrollment potential and follow-up compliance), experience in the treatment of dissection, and participation in other clinical trials. A total of 49 centers were approved to participate in the project. These centers are broadly distributed across the United States, and as mentioned previously, represent multiple specialties and all types of clinical practice.
Project design that led to efficiencies gained. This project uses data without patient, center, and physician identifiers compiled by the SVS PSO, in compliance with the Patient Safety Act, and collected during routine treatment of patients with type B descending aortic dissection. Patients are separated into acute (#30 days) and chronic (>30 days) indications. Only patients with a Stanford type B dissection in native aorta, without an antecedent history of DeBakey type I dissection, are included. The rationale for this distinction lies in the differing natural history of disease in those patients with residual dissection distal to a repaired ascending/ arch aorta. Otherwise, there are no additional exclusion criteria for the project, which ensures capture of real-world use of the devices in these patients. Accordingly, investigator discretion and judgment is surveyed in our study, rather than adherence to prespecified inclusion criteria, which would be more typical model of an industry-sponsored trial.
Further facilitating the efficiency of the project, patients are automatically identified as eligible for enrollment at participating centers based on history and anatomic data once entered in the database, which also avoids selection bias. Centers are contacted periodically by SVS PSO staff to ensure complete data entry, including details of preoperative and postoperative imaging performed as normal care delivery for these patients. To offset the additional effort required for long-term follow-up reporting, centers are reimbursed by the PSO for data entered at the prescribed follow-up intervals. Reimbursement for data entry is based on the completeness of patient data and entering all consecutive cases, which is confirmed by audit of hospital claims data.
Each device manufacturer receives detailed nonidentifiable data for its devices along with aggregate tables of all data summarized from different reporting periods to prevent device-to-device comparisons. Data are reported to the FDA in aggregate format to allow for the monitoring of the use of all TEVAR devices to treat dissection. The FDA also reviews detailed information for each manufacturer's device to monitor safety and effectiveness.
Current project status. Because of the existing network of physicians and centers already entering TEVAR data in the VQI, as well as the ability to retrospectively identify and include patients, site selection and patient inclusion has been very efficient and has exceeded expectations.
The project began on August 10, 2014, and the 5-year cohort of 400 patients completed early patient data entry in June 2016, which was much sooner than projected based on previous industry experience (Fig 2) . As expected from the pattern of previous VQI data collection, the acute dissection subgroup was completed somewhat faster. Importantly, the real-world practice provided a sufficiently balanced number of patients with devices from each manufacturer so that no additional effort was required to capture patients in any particular group. Patient follow-up compliance has been excellent, with >95% follow-up compliance at 1 month and >90% follow-up compliance at 1 year.
DISCUSSION
This project demonstrates innovative and highly efficient real-world evidence generation and assessment of medical devices in a collaborative setting with federal agencies (FDA, AHRQ), physicians, and device manufacturers leveraging an existing national quality improvement registry. The key to the observed project efficiencies was the existence of an established community of clinical expertise and the network of VQI centers already entering much of the clinical data necessary to answer specific postmarket questions regarding device performance and safety. The concept of maximizing the access to real-world data sources and use of realworld evidence is embedded in the most recent FDA strategic priorities, including a recently issued a realworld evidence guidance document, 17 which is currently draft and not for implementation. This shift has evolved and was informed by the foundational work and demonstration projects supported by the FDA via the Medical Device Epidemiology Network (http://mdepinet.org/). Monitoring device performance after approval has historically relied on the Medical Device Reporting system and the Section 522 Postmarket Surveillance Studies Program. 18 Although reporting through the Medical Device Reporting system is mandatory for manufacturers, reporting suffers from the voluntary nature by device users, likely leading to under-reporting, 19 and Section 522 studies often have inclusion/exclusion criteria that limit the ability of the study to capture real-world data. Also, recruiting patients and providers to participate in PAS for devices already approved for use has been historically difficult. The FDA began an initiative in 2012 to improve this multifaceted approach to device surveillance and evaluation. 20 Efficient registry-based real-world data collection has the potential to advance these existing methods of postmarket surveillance. The FDA is currently developing approaches to increase the use of real-world evidence, including registries, to support future regulatory decisions.
The FDA has previously commented that the most successful PASs are those that align with standard practice and follow-up. 21 Although not a conventional PAS, this project further aligns with standard practice, maximizing access to real-world data, which further demonstrates the effect of this approach. Additional data and followup reporting are required for participation in the dissection surveillance project when compared with the basic VQI Thoracic & Complex EVAR Registry, but use of the registry represents a great efficiency compared with collecting data in a separate PAS. This allows minimal additional work effort for study completion beyond the usual quality efforts within a clinical practice, which improves enrollment and decreases the overall burden of the study on participating centers and manufacturers. Rapid assimilation of patient data demonstrates the success of this project construct, which was facilitated by the large number of centers already participating in the VQI, the use of broad inclusion criteria, and the ability to retrospectively include patients. In addition, the registry infrastructure, coupled with the existing auditing system, ensures that true real-world use of TEVAR for type B aortic dissection is being collected. Other national registries in the cardiovascular space (eg, Trancatheter Valve Therapy [TVT] Registry) also play important roles in mandated postmarket studies and surveillance in addition to serving the clinical community. 22 Similar to this VQI project, the key to the success was the multistakeholder public/private engagement. Although the project is still underway and the overall success will be determined upon completion, all indicators suggest that this method of device evaluation provides an opportunity to improve the more traditional approach of manufacturers conducting standalone PAS.
SUMMARY
The VQI TEVAR for type B aortic dissection project provides an exemplary model for performing postmarket observation of medical devices using real-world national data to monitor safety and effectiveness. This approach promotes the FDA CDRH commitment to balance premarket and postmarket data requirements as well as its strategic priority to maximize the use of realworld evidence to support regulatory decision making.
This AHRQ-established PSO activity offers confidentiality for patients, providers, and manufacturers while obtaining information to address questions associated with the treatment of dissections with TEVAR as well as device-specific performance.
In lieu of a traditional enrollment in a stand-alone PAS, patients already participating in the registry were evaluated, allowing rapid completion of initial patient inclusion. Importantly, the project included patients treated by multiple specialists in various practice settings. Thus, this project is well aligned with routine clinical practice and health care quality improvement efforts and incorporates mechanisms to minimize selection bias, missing data, and sensitivities around device-to-device comparisons. The registry also presents an opportunity for linkage with other complementary data sources (eg, administrative claims data, electronic health records) for long-term assessment of patients captured in the registry and will ultimately contribute to the development of a National Evaluation System for Health Technology (NEST). 19, 23 
